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Healthcare decisions should be based on all relevant evidence.1 Usually this is provided by 
randomised controlled trials (RCTs) comparing two or more interventions for a condition 
affecting a target population of interest, although other forms of evidence can be considered.1 
2
 When more than one study is available, meta-analysis can be used to combine multiple 
treatment effects and obtain an overall estimate of the effect in the target population. To 
assess clinical effectiveness, evidence from RCTs is typically used and relative treatment 
effects estimated in individual trials are pooled using methods that preserve within-trial 
randomisation. However, for the majority of health conditions, there are more than two 
interventions of interest. In such cases, performing multiple pairwise meta-analyses 
(comparing interventions two at a time) or lumping every active intervention to be compared 
WRD³FRQWURO´LVRIOLPLWHGXVHfor decision-making and does not allow for coherent and 
transparent decisions. Decisions involving more than 20 interventions are not uncommon.3-6 
The number of pairwise comparisons required to make a decision between 3 interventions is 
3, with 5 interventions it is 10, with 10 interventions it is 45 and with 41 interventions4 it is 
820. Clearly not all comparisons will have been carried out in RCTs but looking at multiple 
separate pairwise analyses carried out using different sets of trials makes it impossible to 
decide which intervention is best. 
Network meta-analysis (NMA), also termed multiple treatment meta-analysis or mixed 
treatment comparisons, was developed as an extension of pairwise meta-analysis to allow 
comparisons of more than two interventions in a single, coherent analysis of all the relevant 
RCTs.7-10 Its main advantages are that it produces consistent estimates of the relative effects 
of all interventions compared to every other in a single analysis using both direct and indirect 
evidence, whilst also correctly incorporating the relative effects from trials with more than 
3 
two arms (i.e. avoiding double counting of patients). This results in greater precision of 
treatment effect estimates and the ability to rank all the interventions in a coherent way.8 As 
for standard meta-analysis, NMA can be performed for most types of RCT outcomes, 
continuous, dichotomous, event rates and from survival models, using an appropriate scale 
(mean difference, odds ratio, relative risk, hazard ratio etc).  
The underlying idea is very simple: consider three friends, Anne, Ben and Charles. If we 
know that Ben is 7cm taller than Anne, and that Charles is 10cm taller than Anne, then we 
know that Charles is 3cm taller than Ben, and is therefore the tallest. We can also rank the 
friends in terms of who is tallest as 1=Charles, 2=Ben, 3=Anne. So, by taking Anne¶VKHLJKW 
as reference and measuring the heights of the others compared to hers, we know how 
HYHU\RQH¶VKHLJKWFRPSDUHVWRHDFKRWKHUand how to order the friends by height. The only 
assumption being made is that the heights we measured are an accurate reflection of the true 
heights of the three friends (in other words, that we used a sufficiently accurate measuring 
tool). It is easy to see that the same relative heights and ranks would be obtained if one of the 
male friends had been the reference, and how the height relationships would extend if more 
than three friends had been measured. This is exactly how NMA works, although we also 
take the uncertainty (i.e. the sampling error) in the relative effect estimates into account, as is 
standard in meta-analysis. 
Suppose we are interested in comparing treatments B and C. We find one trial comparing B 
to A, giving a mean difference (MD) of -2.3 with a standard error (SE) of 0.45 and one trial 
comparing C to A giving a mean difference of -4 with SE 0.5. This suggests that both 
treatments B and C are better than A with 95%CIs that exclude no effect: (-3.18, -1.42) for B 
compared to A and (-4.98, -3.02) for C compared to A (assuming a reduction in the mean is 
desirable, eg for pain). The network formed by these comparisons is given in Figure 1. In the 
4 
absence of a direct RCT, what can we say about the relative effect of treatment C vs B? The 
first thing to note is that this question can only be answered in the context of a pre-defined 
patient population of interest. That is, one must ensure that the populations included in the 
BvsA and the CvsA trials are comparable to each other and to our target population, with 
respect to any potential effect modifying characteristics.10 Once it is decided that these 
studies were carried out on clinically homogeneous populations (which, in turn, are similar to 
the target population) then it can be assumed that each study estimates the true treatment 
effects in the target population (i.e. WKHUHODWLYHHIIHFWVZHUHPHDVXUHGXVLQJDQµDFFXUDWH
PHDVXUHPHQWWRRO¶. We can therefore say that C is better than B by 1.7 units through the 
indirect comparison of treatments C and B,11 since the true treatment effects of BvsA, CvsA 
and CvsB must be consistentLHWKH\PXVWDGGXSLQWKHVDPHZD\DVWKHIULHQGV¶KHLJKWV. In 
other words, the mean difference (MD) of C compared to B must be the difference between 
the MDs of CvsA and BvsA, which is -1.7 units. This consistency relationship, sometimes 
also called transitivity, must hold if the studies are estimating the true effects in a patient 
population. To obtain a 95%CI for the CvsB comparison we simply add the variances of the 
two other comparisons to obtain a SE with which a 95%CI can be constructed: (-3.01, -0.39). 
7KLVW\SHRIFRPSDULVRQLVWHUPHGµLQGLUHFW¶DVLWUHOLHVRn evidence against the comparator A, 
and not on µdirect¶ head to head evidence from one or more trials of CvsB.  
Suppose now that we also had evidence from a new study on the same patient population 
which compared treatment C to B, giving a mean difference of -1.8 95%CI (-3.66, 0.06). 
Traditional hierarchies of evidence state that estimates from direct head-to-head RCTs 
SURYLGHWKH³EHVWDYDLODEOH´HYLGHQFHRILQWHUYHQWLRQHIIHFWs. Should we now discard the 
indirect evidence? Or perhaps we should prefer the indirect evidence since it suggests a 
statistically significant effect? To do either is contrary to the principle of using all relevant 
evidence for decision making.1 12 The solution is to use both the direct and indirect evidence 
5 
to do a mixed (evidence) treatment comparison, or NMA, under the assumption that both the 
direct and indirect evidence are estimating the same, true, underlying treatment effect of 
CvsB in our target population. The exact same principles apply when multiple RCTs are 
available for each of the possible comparisons and for more than three interventions.  
NMA relies on the same assumptions underlying pairwise meta-analysis, that is, that the 
included studies are sufficiently homogenous in terms of the condition being studied, the 
included participants and the definition of active and control interventions. In other words, 
we are assuming that the effects of BvsA and CvsB that would have been observed if the 
CvsA RCT had included all three treatments, is the same as that observed in the BvsA RCT 
(apart from sample variability). This assumption is the basis for coherent decisions whether 
they involve two or more treatments. One way to empirically check this is to ask: ³JLYHQWKH
known study and participant characteristics, if all these studies compared the same two 
treatments, would it be suitable to combine them in a meta-DQDO\VLV"´,IWKHDQVZHUWRWKLVLV
yes, and the only distinction is that instead the studies compare different sets of interventions, 
WKHQWKHDVVXPSWLRQRI³VXIILFLHQWKRPRJHQHLW\´LVLQSULQFLSOHVDWLVILHG 
Because NMA pools the relative treatment effects estimated across RCTs, within-trial 
randomisation is preserved. As long as the interventions of interest form a connected network 
of comparisons, then relative effects of each intervention compared to every other can be 
obtained, along with estimates of their uncertainty (e.g. 95% confidence intervals). Figure 2 
shows two networks of tocolytic interventions compared in a guideline produced for the 
National Institute for Health and Care Excellence (NICE)13 which updated a previously 
published systematic review and NMA.14 Nine types of tocolytic interventions were of 
interest (Table 1) and 98 RCTs were included. To ensure that the assumption of consistency 
of treatment effects was reasonable, the study characteristics and possible effect modifiers 
6 
were first assessed by the reviewers.14 For example, the analysis excluded trials in which 
women were at high risk of preterm delivery such as those with multiple gestation and 
ruptured membranes. Underpinning this exercise is the need to determine if every individual 
included in every trial across the network could have been (hypothetically) randomised to any 
of the included treatments. If, for example, a treatment would only be administered to a 
multiparous and not nulliparous woman or as a second- or third-line treatment, it is possible 
that the assumption of consistency might not hold.  
 
Table 1 Tocolytic therapies of interest 
 
Interventions 
1 Placebo/control 
2 Prostaglandin inhibitors 
3 Magnesium sulfate 
4 Betamimetics 
5 Calcium channel blockers 
6 Nitrates 
7 Oxytocin receptor blockers  
8 Alcohol/ethanol 
9 Other treatments 
 
The first network (Figure 2a) includes 47 RCTs reporting on perinatal death. It is 
³connected´ as there is a path that connects every treatment and therefore all relative effects 
for all interventions compared to every other can be obtained. We can see that the 
interventions with the most patients randomised are (in decreasing order) Betamimetics and 
Placebo, as they have the widest circles. The second network, Figure 2b), includes the 51 
RCTs which reported on estimated gestational age (EGA) at delivery. This figure has two 
disconnected interventions: µAlcohol/ethanol¶ and µOther treatments¶ cannot be compared to 
the rest of the network. For this outcome, comparisons can only be made between the other 
interventions. More information can be added to these plots to show other network 
7 
characteristics14 15 although the ability to display additional information can be limited by the 
size of the network. 
 
10$02'(/6$1'(67,0$7,1*75($70(17())(&76 
NMA simultaneously combines the relative treatment effects estimated within each study 
whilst accounting for the individual treatments being compared and correctly incorporating 
studies with more than two arms. Fixed or random effects models can be fitted, the latter 
allows for between-study heterogeneity. NMA random effects models usually assume that the 
between-study heterogeneity is the same across all comparisons, that is, a single measure of 
heterogeneity is calculated across the whole network, although models allowing for different 
heterogeneity for each comparison can also be fitted.16 In the presence of large heterogeneity, 
patient or study characteristics that may modify the relative treatment effects (effect 
modifying covariates) should be investigated using meta-regression17 or sensitivity analyses. 
As a statistical model, NMA can be fitted using a frequentist or Bayesian approach.18 A 
Bayesian approach to NMA requires a prior probability distribution to be specified for the 
parameter of interest (e.g. treatment effect), describing the range and probability of plausible 
values for the parameters, which is combined with a likelihood statement, which describes 
the data collected, using Bayes theorem. This produces a posterior distribution which 
describes the new range and probability of plausible values for the parameter, on which 
statistical inferences are based.19 Uncertainty in the parameters is fully represented by their 
posterior distributions, so direct probability statements can be made on e.g. the probability 
that treatment X increases EGA at delivery by 4 weeks. Consequently, Bayesian NMAs are 
more commonly used as they naturally produce ranking and probability outputs useful for 
8 
decision-making and allow for greater flexibility in the models fitted.10 )RUH[DPSOHD³FODVV
PRGHO´FDQEHXVHGZhere interventions that have a similar mode of action (ie belong to the 
VDPH³FODVV´DUHDVVXPHGWRKDYHVLPLODUEXWQRWLGHQWLFDOHIIHFWVFRPSDUHGWRWKH
reference treatment as used in the tocolytics example13 14 (Figure 2 shows the networks at 
class level). This allows an overall decision to be made at a class level, but individual 
treatment profiles and costs can also be incorporated in clinical or health economic decisions. 
When data are sparse, for example for adverse or rare events, Bayesian methods have 
additional advantages such as the ability to better handle studies with zero cells and the 
potential for including any relevant prior information. However, for most NMAs only simple 
models are required and no prior information is used, with Bayesian approaches typically 
defining non-informative prior distributions for all treatment effect parameters, making 
results from frequentist or Bayesian analyses very similar. The main difference between these 
approaches is how results are presented. Results from a frequentist NMA will be presented as 
estimated relative effects (eg MD, odds ratio,OR, etc) and a 95% confidence interval (CI), 
whereas results from a Bayesian analysis will be presented as summaries from the posterior 
distribution of the MD (or OR), which can be the mean or median MD (OR etc) and their 
95% credible interval (CrI).15 A credible interval is interpreted as the interval where there is a 
95% probability that the values of the MD (OR etc) will lie. Medians are recommended for 
ratio measures such as the OR, hazard ratio or risk ratio, whereas either the mean or median 
can be reported for the MD or standardised mean difference. 
Regardless of the framework used, the fit of the model to the data should be assessed, and in 
networks with both direct and indirect evidence contributing to estimates, the assumption of 
consistency should also be statistically assessed. This can be done by comparing the results 
obtained using the direct evidence alone, to the results obtained using the indirect evidence 
9 
alone,20 21 and calculating a p-value for their difference. Methods that assess consistency in 
the whole network22 23 are also available and often preferred when networks are large.10 
Should evidence of inconsistency be found, the characteristics of all included studies should 
be re-examined and adjustment for effect modifiers (eg covariates or risk of bias) should be 
considered. 
5(3257,1*$1',17(535(7,1*5(68/76 
Table 2 reports the mean differences in EGA (in weeks) with their 95% CrIs. Colloquially 
kQRZQDVDµWULDQJOHWDEOH¶it displays findings from different analyses, in this case from the 
direct, pairwise analyses and the NMA analysis. Values shown in the upper diagonal are the 
MDs for the column header versus the row header and are derived from the NMA, and values 
in the lower diagonal are the MDs for the row header versus the column header. This ensures 
that the values are easily comparable across the two analyses. For example, the MD estimated 
from the NMA (upper diagonal) for prostaglandin inhibitors vs placebo is 2.32 (95% CrI 1.27 
to 3.35), suggesting that there is evidence that the intervention increases EGA at delivery, by 
2.3 weeks, compared to placebo. In addition we can say that there is a 95% probability that 
this increase is between 1.27 and 3.35 weeks. We can compare this to the MD estimated from 
the direct evidence alone (lower diagonal) 3.27 (95% CrI 1.68 to 4.78). The first thing to note 
is that the point estimates are close and the 95% CrIs overlap considerably. However, the 
95% CrIs from the NMA are more precise. In contrast, the MD of Magnesium sulfate 
compared to Placebo estimated from the direct evidence and the NMA appear contradictory, 
with estimates in opposite direction, although the very wide 95%CrI for the pairwise meta-
analysis overlap with those obtained from the NMA, which are also narrower. The 
consistency assumption was checked13 and some evidence of conflict between direct and 
indirect evidence was identified for this comparison (indirect OR=1.29 (95% CrI 0.29 to 
10 
2.27), p-value=0.015). No explanation was found for this conflict but it was taken into 
account when making decisions. 
The empty cells in the lower diagonal denote that no direct evidence was available for that 
comparison (for example, Calcium channel blockers vs Placebo), whereas the NMA can 
make all the comparisons and show that there is evidence of an increase in EGA at delivery 
for all interventions compared to Placebo, except Oxytocin receptor blockers (MD 0.68 95% 
CrI -1.32 to 2.67).  
11 
 
Table 2 Mean differences and 95% CrI for EGA at delivery (in weeks) from the pairwise and network meta-analyses. The upper diagonal displays the mean 
differences for the column intervention versus the row intervention, derived from the NMA. Values greater than 0 favour the column defining intervention. The 
lower diagonal displays the mean differences for the row intervention versus the column intervention, derived from direct comparisons only. Values greater than 0 
favour the row defining the intervention. (Adapted from the NICE guideline13).  
na: not available. 
. 
Placebo/ 
control 
Prostaglandin 
inhibitors 
Magnesium 
sulfate Betamimetics 
Calcium 
channel 
blockers Nitrates 
Oxytocin 
receptor 
blockers 
Placebo/ control   
2.32 
(1.27,3.35) 
1.29 
(0.29,2.27) 
1.25 
(0.40,2.07) 
1.69 
(0.69,2.66) 
1.65 
(0.52,2.78) 
0.68 
í 
Prostaglandin 
inhibitors 
3.27 
(1.68,4.78)   
í1.04  
íí 
í1.08  
íí 
í0.64 
í 
í0.67 
í 
í1.65 
í 
Magnesium 
sulfate 
í0.14 
í 
í0.23 
í45,0.97)   
-0.04 
í 
0.40 
í 
0.36 
í 
í0.61 
í 
Betamimetics 
1.91 
(0.90,2.90) 
í1.56 
í 
í0.19 
í   
0.44 
í 
0.40 
í 
í0.57 
í 
Calcium channel 
blockers na 
í0.53 
í 
í0.02 
í 
0.80 
í   
í0.03 
í 
í1.01 
í 
Nitrates 
0.17 
í2,2.06) na na 
í0.58 
í 
1.30 
(í1.07,3.68)   
í0.98 
í 
Oxytocin 
receptor blockers 
0.90 
í1.74,3.53) na na na 
í1.21 
(í3.66,1.23) na   
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Triangle tables can also be used to report two different outcomes, with one in the top half and 
the other in the bottom half. This can be a good way to display results from two important 
outcomes, for example effectiveness and acceptability24 or other closely related outcomes,4 
although it can be limited by the required width when there are many interventions. Similar 
vertical displays can convey the same information14 15 and relative effects can also be 
presented as forest plots.13 14 
 
Table 3 Posterior rank statistics and probabilities for the outcome EGA at delivery. 
 Rank statistics Probabilities 
Interventions mean median 95%CrI best top 3 
Placebo/control 6.74 7 (6,7) 0.00 0.00 
Prostaglandin inhibitors 1.38 1 (1,4) 0.74 0.97 
Magnesium sulphate 4.26 4 (2,6) 0.01 0.28 
Betamimetics 4.48 5 (2,6) 0.00 0.16 
Calcium channel blockers 2.84 3 (1,5) 0.07 0.76 
Nitrates 3.04 3 (1,6) 0.13 0.65 
Oxytocin receptor blockers 5.27 6 (1,7) 0.05 0.19 
 
Table 3 shows treatment rankings and the probability that each intervention (or class) is the 
µEHVW¶or in the top 3 for EGA at delivery. Here ranks are reported for effectiveness, such that 
rank 1 means the intervention is most effective. Placebo has a mean rank of 6.74 and a 
median rank of 7 (95% CrI 6 to 7). That is, on average, placebo was ranked approximately 7th 
out of 7 treatments (i.e. worst) for gestational age at delivery. Conversely, prostaglandin 
inhibitors were ranked 1st out of all 7 treatment classes and had a 74% probability of being 
the most effective treatment and a 97% probability of being in the top three treatment classes 
to increase EGA.  
13 
An alternative way of reporting ranks is to consider the cumulative probabilities using the 
surface under the cumulative ranking curve (SUCRA)25 which transforms the cumulative 
probabilities into a single value between 0 and 1, where a larger value indicates the more 
effective treatment. This is often reported as a percentage.15  
All probabilities, SUCRA values and rankings should be interpreted with caution as they are 
very sensitive to the uncertainty in the relative treatment effects used to produce them. 
Measures or displays which capture this uncertainty such as a table of rank statistics with 
95% CrI (Table 3), rank probability plots (rankograms)10 14 25 or cumulative ranking 
probability plots15 25 should be reported in preference to single values such as the probability 
of being best or SUCRA. It is also imperative that ranking results are considered alongside 
the estimates of relative treatment effects as a treatment could have a higher rank without 
evidence of having a better effect than any of the others.  
Importantly, all results should be interpreted taking into account the uncertainty in the 
estimates (conveyed by the 95% CrI) as well as the risk of bias in the included evidence. 
Tools that allow an examination of the impact of studies at risk of bias,26 27 and the impact of 
changes in the evidence on the decision28 have been developed and can help to interpreting 
the findings from a NMA. 
&21&/86,216 
When more than two interventions are being considered, synthesis of RCTs using an NMA 
will ensure that all the relevant evidence, whether direct or indirect, is used to produce 
coherent estimates of the relative effects of every intervention compared to every other. This 
allows for more efficient use of the relevant evidence which can increase the precision of the 
estimates. In addition, because multiple sources of evidence are used, the final estimates are 
14 
more robust than if only direct sources of evidence were included, that is they are less likely 
to be influenced by the inclusion or exclusion of a single trial. The underlying assumption is 
that there are no participant or study characteristics that would modify the relative treatment 
effect of each treatment compared to every other. 
Relying on multiple pairwise meta-analyses, each including a different set of trials may lead 
to incoherent decisions and does not make the best use of the available evidence. 
It is important to display NMA results carefully to aid interpretation and to clinically and 
statistically assess the plausibility of the assumptions made.  
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Figure 1 An example of a network of 3 treatments compared in two trials (solid black lines) where and 
indirect comparison can be made (dashed grey line). MD: mean difference; SE: standard error. 
 
 
19 
Figure 2 Network plots for a) perinatal death and b) EGA at delivery. The size of the circles is 
proportional to the number of patients randomised to each intervention and width of the lines is 
proportional to the number of studies making each comparison. Data from NICE guideline13 
 
 
